Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT07620210
Recruiting Not applicable

Effects of CTAR and a Swallowing Pressure Ball in Older Stroke Adults

NCT07620210 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2026-03-18
Last updated
2026-06-03

Condition(s) studied

StrokeDysphagiaPost-Stroke Dysphagia

Investigational drug(s) / intervention(s)

Innovative Swallowing Pressure Measurement Ball Combined With CTAR TrainingConventional Swallowing Rehabilitation

Innovative Swallowing Pressure Measurement Ball Combined With CTAR Training: Participants receive Chin Tuck Against Resistance (CTAR) swallowing training combined with an innovative swallowing pressure measurement ball intervention twice daily for 12 weeks.

Conventional Swallowing Rehabilitation: Participants receive conventional swallowing rehabilitation including tongue resistance exercise and oral motor control training.

Study summary

This study aims to investigate the effectiveness of resistance swallowing rehabilitation using Chin Tuck Against Resistance (CTAR) exercises combined with an innovative swallowing pressure ball in improving swallowing function and swallowing-related quality of life among home-based older stroke patients with dysphagia.

Participants will receive a 12-week swallowing rehabilitation program conducted in the home-care setting. Outcome measures include swallowing function assessments, swallowing-related quality of life, and rehabilitation adherence. The study is designed as a randomized controlled trial to explore the feasibility and clinical benefits of resistance-based swallowing rehabilitation in community and home-care environments.

Eligibility

Sex
ALL
Min age
65 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 65 and 90 years. * Diagnosed with ischemic or hemorrhagic stroke more than 6 months prior to enrollment. * Receiving home care services from participating home care agencies. * Able to follow instructions and participate in swallowing training. * MMSE score ≥24, or adjusted according to education level. * Passed the second stage of the 3-step swallowing screening test. * Presence of post-stroke dysphagia symptoms. Exclusion Criteria: * History of head and neck cancer or head and neck radiotherapy. * History of cervical spine surgery or tracheostomy. * Severe neurological or neuromuscular diseases affecting swallowing function. * Severe unstable medical conditions. * Current use of medications significantly affecting swallowing function or muscle tone. * Unable to complete the intervention or follow-up assessments. * Receiving tube feeding without oral intake ability.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
ChiMei Medical Center Tainan Tainan City Recruiting

More Chimei Medical Center trials in Taiwan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07620210 on ClinicalTrials.gov ↗ ← All trials in Taiwan